Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex fair value estimate is US$32.91 Vertex's US$19.50 ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Vertex Pharmaceuticals will use Orum Therapeutics’ dual-precision targeted protein degradation (TPD² ®) technology platform to discover targeted conditioning agents for use with gene editing therapies ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will ...

Vertex Flooring introduces distinctive marquetry flooring crafted with expert precision, offering custom wood designs ...